BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bou Khalil R. Atypical Antipsychotic Drugs, Schizophrenia, and Metabolic Syndrome in Non–Euro-American Societies. Clinical Neuropharmacology 2012;35:141-7. [DOI: 10.1097/wnf.0b013e31824d5288] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Fu L. Metabolic syndrome in patients with schizophrenia: Why should we care. Medicine (Baltimore) 2022;101:e29775. [PMID: 35960125 DOI: 10.1097/MD.0000000000029775] [Reference Citation Analysis]
2 Zhuo C, Liu W, Jiang R, Li R, Yu H, Chen G, Shan J, Zhu J, Cai Z, Lin C, Cheng L, Xu Y, Liu S, Luo Q, Jin S, Liu C, Chen J, Wang L, Yang L, Zhang Q, Li Q, Tian H, Song X; China multiple organs damage in the mental disorder (CMODMD) Group. Metabolic risk factors of cognitive impairment in young women with major psychiatric disorder. Front Psychiatry 2022;13:880031. [DOI: 10.3389/fpsyt.2022.880031] [Reference Citation Analysis]
3 Ishigooka J, Nakagome K, Ohmori T, Iwata N, Inada K, Iga JI, Kishi T, Fujita K, Kikuchi Y, Shichijo T, Tabuse H, Koretsune S, Terada H, Terada H, Kishimoto T, Tsutsumi Y, Kanda Y, Ohi K, Sekiyama K. Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study. Psychiatry Clin Neurosci 2021. [PMID: 34626144 DOI: 10.1111/pcn.13304] [Reference Citation Analysis]
4 Idrus F, Singara T, Sunarto D, Syamsuddin S, Lisal ST. Abnormalities in Glucose Blood Level during Antipsychotic Treatment in Schizophrenia Patients. Open Access Maced J Med Sci 2021;9:340-344. [DOI: 10.3889/oamjms.2021.6294] [Reference Citation Analysis]
5 Naguy A, Pridmore S, Alamiri B. Adjuvant Pitolisant in a Case With Early-Onset Schizophrenia. Clin Neuropharmacol 2021;44:229-30. [PMID: 34456229 DOI: 10.1097/WNF.0000000000000472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zhang Q, He H, Bai X, Jiang L, Chen W, Zeng X, Li Y, Teixeira AL, Dai J. Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese. Front Psychiatry 2021;12:702720. [PMID: 34305687 DOI: 10.3389/fpsyt.2021.702720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bourassa KA, Postolache TT, Dagdag A, Fuchs D, Okusaga OO. Plasma soluble P-selectin correlates with triglycerides and nitrite in overweight/obese patients with schizophrenia. Pteridines 2020;31:61-7. [PMID: 32982068 DOI: 10.1515/pteridines-2020-0012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Valle R. Review of Early Intervention Programmes in Psychosis: Implementation Proposal for Peru. Rev Colomb Psiquiatr (Engl Ed) 2020;49:178-86. [PMID: 32888661 DOI: 10.1016/j.rcp.2018.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Valle R. Review of early intervention programmes in psychosis: implementation proposal for Peru. Revista Colombiana de Psiquiatría (English ed ) 2020;49:178-186. [DOI: 10.1016/j.rcpeng.2018.11.001] [Reference Citation Analysis]
10 Doretto L, Mari FC, Chaves AC. Polycystic Ovary Syndrome and Psychotic Disorder. Front Psychiatry 2020;11:543. [PMID: 32587538 DOI: 10.3389/fpsyt.2020.00543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
11 Boiko AS, Mednova IA, Kornetova EG, Bokhan NA, Semke AV, Loonen AJM, Ivanova SA. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia. Neuropsychiatr Dis Treat 2020;16:1051-8. [PMID: 32368067 DOI: 10.2147/NDT.S247161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
12 Zhang X, Yang M, Du X, Liao W, Chen D, Fan F, Xiu M, Jia Q, Ning Y, Huang X, Wu F, Soares JC, Cao B, Wang L, Chen H. Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia. Mol Psychiatry 2020;25:3220-30. [PMID: 31409883 DOI: 10.1038/s41380-019-0478-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
13 Xu H, Zhuang X. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. Neuropsychiatr Dis Treat 2019;15:2087-99. [PMID: 31413575 DOI: 10.2147/NDT.S208061] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
14 Boiko AS, Mednova IA, Kornetova EG, Semke AV, Bokhan NA, Loonen AJM, Ivanova SA. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. Heliyon 2019;5:e02033. [PMID: 31317083 DOI: 10.1016/j.heliyon.2019.e02033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
15 Chen J, Huang XF, Shao R, Chen C, Deng C. Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes. Front Neurosci 2017;11:643. [PMID: 29209160 DOI: 10.3389/fnins.2017.00643] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 7.7] [Reference Citation Analysis]
16 Chen CC, Hsu LW, Huang KT, Goto S, Chen CL, Nakano T. Overexpression of Insig-2 inhibits atypical antipsychotic-induced adipogenic differentiation and lipid biosynthesis in adipose-derived stem cells. Sci Rep 2017;7:10901. [PMID: 28883496 DOI: 10.1038/s41598-017-11323-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
17 Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777. [PMID: 28721057 DOI: 10.2147/tcrm.s117321] [Cited by in Crossref: 219] [Cited by in F6Publishing: 230] [Article Influence: 36.5] [Reference Citation Analysis]
18 Róg J, Karakuła-juchnowicz H. Omega – 3 fatty acids in schizophrenia – part I: importance in the pathophysiology of schizophrenia. Current Problems of Psychiatry 2016;17:198-213. [DOI: 10.1515/cpp-2016-0021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Trifiró G, Sultana J, Spina E. Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. Drug Saf. 2014;37:501-520. [PMID: 24859163 DOI: 10.1007/s40264-014-0170-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
20 Richly P, López P, Gleichgerrcht E, Flichtentrei D, Prats M, Mastandueno R, Bustin J, Cetkovich-Bakmas M. Psychiatrists’ approach to vascular risk assessment in Latin America. World J Psychiatr 2014; 4(3): 56-61 [PMID: 25250222 DOI: 10.5498/wjp.v4.i3.56] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Lin EC, Shao WC, Yang HJ, Yen M, Lee SY, Wu PC, Lu RB. Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics? Metab Brain Dis 2015;30:107-13. [PMID: 25034455 DOI: 10.1007/s11011-014-9587-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
22 Chue P, Neagu B. Antipsychotic Drugs. Side Effects of Drugs Annual 2014. [DOI: 10.1016/b978-0-444-63407-8.00006-x] [Reference Citation Analysis]